Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.3
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ (3,107) $ (14,852) $ (9,159) $ (30,248)
General and administrative (1,780) (1,833) (5,867) (5,789)
Total operating expenses (4,887) (16,685) (15,026) (36,037)
Operating loss (4,887) (16,685) (15,026) (36,037)
Interest expense, net (590) (300) (1,648) (1,023)
Adjustments to fair value of derivatives (433) 13,199 (1,226) 11,361
Other (expense) / income, net (48) 70 (77) 161
Total other (expense) / income (1,071) 12,969 (2,951) 10,499
Loss before income taxes (5,958) (3,716) (17,977) (25,538)
Income tax expense (136) (161) (215) (471)
Net loss $ (6,094) $ (3,877) $ (18,192) $ (26,009)
Net loss per share - basic $ (0.3) $ (0.3) $ (1.05) $ (2.02)
Net loss per share - diluted $ (0.3) $ (0.3) $ (1.05) $ (2.02)
Weighted average ordinary shares outstanding - basic 20,044,270 13,039,437 17,352,918 12,888,869
Weighted average ordinary shares outstanding - diluted 20,044,270 13,039,437 17,352,918 12,888,869
Other comprehensive income:        
Net loss $ (6,094) $ (3,877) $ (18,192) $ (26,009)
Unrealized gain on marketable securities 3 29 1 353
Comprehensive loss $ (6,091) $ (3,848) $ (18,191) $ (25,656)